Nadir Görülen Malign Mide Tümörlerinde Cerrahi Tedavi Sonuçlarımız

Yıl 2022, Cilt: 9 Sayı: 2, 137 - 141, 24.08.2022

Ramazan Gündoğdu , Hakan Yabanoğlu , Serkan Erkan , Murat Kuş

https://doi.org/10.47572/muskutd.863350

Öz

Mide kanserleri yaygın görülme oranı ve yüksek mortalitesi nedeniyle halen önemini koruyan bir hastalıktır. En sık görülen histopatolojik alt tipi adenokanserlerdir. Nadir görülen mide kanserlerinin saptanması klinik şüphe ve ek tetkikler gerektirebilmektedir. Bu çalışmada gastrektomi yapılan; nadir görülen histopatolojik tanılı 22 mide kanseri hastasının klinik ve cerrahi tedavi sonuçlarının literatür eşliğinde sunulması amaçlanmıştır. Merkezimizde Ocak 2011-Ekim 2020 tarihleri arasında malign nedenle gastrektomi uyguladığımız hastaların dosyaları geriye dönük incelendi. Nadir gözlenen histopatolojik tanılı ve verilerine ulaşılabilen 22 hasta çalışmaya alındı. Hastaların dosyaları geriye dönük incelenerek yaş, cinsiyet, gastroskopi bulguları, gastroskopik biyopsi, uygulanan cerrahi prosedür, ek tetkik, patoloji raporları, tümör çapı, takip süresi, nüks ve mortalite bilgileri kaydedildi. Çalışmaya 11’i erkek, 11’i kadın 22 hasta dahil edildi. Hastaların yaş ortalaması 53 (18-77) idi. Biyopsilerinde malignite saptanmayan dört hastanın ikisi EUS, biri PET-CT, biri MR bulgularında maligniteden şüphelenilmesi sonrasında opere edildi. Hastaların 12’si GİST, beşi nöroendokrin tümör, ikisi Non Hodkin Lenfoma, ikisi leiomyosarkom, biri skuamoz hücreli karsinomdu. Ortalama takip süresi 36 (0.3-108) aydı. Mide lezyonlarında olası nadir görülen mide kanserlerinin atlanmaması için ek görüntüleme yapılması ve deneyimi yüksek merkezlerce yönetimi önem taşımaktadır. 

Anahtar Kelimeler

Gastrointestinal Stromal Tümör, Leiomyosarkom, Mide Kanseri, Mide Nöroendokrin Tümör

Destekleyen Kurum

başkent üniversitesi

Proje Numarası

KA20/376

Our Surgical Treatment Results in Rare Malign Stomach Tumors

Öz

Stomach cancers are still an important disease due to their prevalence and high mortality. The most common histopathological subtype is adenocancers. Detection of rare gastric cancers may require clinical suspicion and additional tests. In this study, gastrectomy was performed; It is aimed to present the clinical and surgical treatment results of 22 gastric cancer patients with a rare histopathological diagnosis in the light of literature. The files of patients, who underwent gastrectomy for malignant reasons between January 2011-October 2020 in our center, were retrospectively reviewed. Twenty-two patients with rare histopathological diagnosis and available data were included in the study. The files of the patients were examined retrospectively, and information on age, gender, gastroscopy findings, gastroscopic biopsy, surgical procedure, additional examination, pathology reports, tumor diameter, follow-up time, recurrence and mortality information were recorded. Twenty-two patients, 11 males, 11 females, were included in the study. The mean age of the patients was 53 (0.3-108). Of the four patients who had no malignancy in their biopsies, two were operated after EUS, one PET-CT, one after suspected malignancy in MR findings. Of the patients, 12 were GIST, five were neuroendocrine tumors, two were non-Hodkin lymphoma, two were leiomyosarcoma, and one were squamous cell carcinoma. The mean follow-up time was 36 (0.3-108) months. Additional imaging and management by centers with high experience are important in order not to miss possible rare gastric cancers in gastric lesions.

Anahtar Kelimeler

Gastrointestinal Stromal Tumor, Leiomyosarcoma Gastric Cancer, Gastric Neuroendocrine Tumor

Proje Numarası

KA20/376

Kaynakça

• 1. Johnston FM, Beckman M. Updates on Management of Gastric Cancer. Curr Oncol Rep. 2019;21(8):67.
• 2. Zhou K, Faraz A, Magotra M, ve ark. Exophytic primary gastric squamous cell carcinoma and H. pylori gastritis. BMJ Case Rep. 2019;12(7):230-310.
• 3. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol. 2018;24(26):2818-32.
• 4. Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc 2014;47:478-89.
• 5. Leake PA, Cardoso R, Seevaratnam R, ve ark. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer. 2012;15(S1):38-47.
• 6. Karimi P, Islami F, Anandasabapathy S, ve ark. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700-13.
• 7. Dias AR, Azevedo BC, Alban LBV, ve ark. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig. 2017;30(2):150-4.
• 8. Sato Y, Hashimoto S, Mizuno K, ve ark. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817-28.
• 9. Crosby DA, Donohoe CL, Fitzgerald L, ve ark. Gastric neuroendocrine tumours. Dig Surg. 2012;29:331-48.
• 10. Mantese G. Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Curr Opin Gastroenterol. 2019;35(6):555-9.
• 11. Akahoshi K, Oya M, Koga T, ve ark. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 2018;24(26):2806-17.
• 12. Yang Z, Feng X, Zhang P, ve ark. China Gastrointestinal Stromal Tumor Study Group (CN-GIST). Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review. Surg Endosc. 2019;33(9):2982-90.
• 13. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973-83.
• 14. Hohenberger P, Ronellenfitsch U, Oladeji O, ve ark. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg. 2010;97(12):1854-9.
• 15. Ceniceros-Cabrales AP, Sánchez-Fernández P. Perforated gastric diffuse large B-cell lymphoma: A case report and literature review. Rev Gastroenterol Mex. 2019;84(3):412-4.
• 16. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17(6):697–707.
• 17. Juárez-Salcedo LM, Sokol L, Chavez JC, ve ark. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment. Cancer Control. 2018;25(1):1073274818778256.
• 18. Weledji EP, Enoworock G, Ngowe MN. Gastric leiomyosarcoma as a rare cause of gastric outlet obstruction and perforation: a case report. BMC Res Notes. 2014;7:479.
• 19. Aggarwal G, Sharma S, Zheng M, ve ark. Primary leiomyosarcomas of the gastrointestinal tract in the post-gastrointestinal stromal tumor era. Ann Diagn Pathol. 2012;16(6):532-40.
• 20. O’Hanlon DM, Griffin SM. Management of other oesophageal and gastric neoplasms. Upper Gastrointestinal surgery. A companion to specialist surgical practice. Edited by: Michael Griffin S, Raimes SA. 2000, London, NW1 7DX, England: WB Saunders Company Ltd.
• 21. Connolly EM, Gaffney E, Reynolds JV: Gastrointestinal stromal tumours. Br J Surg. 2003;90:1178-86.
• 22. Hwang SH, Lee JH, Kim K, ve ark. Primary squamous cell carcinoma of the stomach: A case report. Oncol. Lett. 2014;8:2122-4.
• 23. Chen Y, Zhu H, Xu F, ve ark. Clinicopathological characteristics, treatment, and prognosis of 21 patients with primary gastric squamous cell carcinoma. Gastroenterol Res Pract. 2016;2016:1-6. 24. Yüksel BC, Uçar NS, Yıldız Y, ve ark. Mide kanserinde standart D2 diseksiyona karşı D1 diseksiyonun mortalite ve morbidite çalışması. Ulus Cerrahi Derg. 2009;25:87-91.